Noves
convocatòries 7PM Salut
La Comissió Europea ha publicat, amb data 20 de juliol de
2010, dues convocatòries del tema “Salut” del
programa de Cooperació del Setè Programa Marc europeu de
R+D, a més de una convocatòria ERANET què també forma part
aquest tema. Aquestes convocatòries pertanyen al
Programa de Treball 2011 (http://cordis.europa.eu/fp7/wp-2011_en.html).
La informació completa de cada convocatòria la trobareu fent
clic en el codi respectiu. Si teniu problemes d’accés amb
l’enllaç, podeu tallar i apegar l’adreça completa al vostre
navegador.
Els terminis de presentació de propostes finalitzen en els
dies esmentats a les 17 hores (hora local de Brusel·les).
PROGRAMA ESPECÍFIC DE COOPERACIÓ
Tema: Salut
FP7-HEALTH-2011-single-stage
http://cordis.europa.eu/fp7/dc/index.cfm?fuseaction=UserSite.CooperationDetailsCallPage&call_id=323#infopack
Pressupost indicatiu: 160.500.000 euros
Data límit: 10 de novembre de 2010
Temes convocats:
1.BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES
FOR HUMAN HEALTH. 1.1 HIGH-THROUGHPUT RESEARCH, 1.1-3: Highthroughput
proteomics for human health and disease.
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS.
1.4-4: High impact research initiative for better
immunisation. 1.4-5: New therapeutic approaches in chronic
inflammatory and autoimmune diseases.
2. TRANSLATING RESEARCH FOR HUMAN HEALTH.2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES:
LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY. 2.1.1
Large-scale data gathering. 2.1.1-1: High impact
research initiative on the human epigenome. 2.1.1-4:
Population genetics studies on cardio-metabolic disorders in
EU/AC and EECA populations.
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN
DEVELOPMENT AND AGEING. 2.2.1. Brain and
brain-related diseases. 2.2.1-4: Creating clinical
and molecular tools for experimental therapy of paediatric
neurodegenerative disorders causing childhood dementia in
Europe and India.
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:
TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH. 2.3.1.
Anti-microbial drug resistance. 2.3.1-2:
Multidisciplinary research on the evolution and transfer of
antibiotic resistance. 2.3.1-3: Management of Gram negative
multi-drug resistant infections.
2.3.3. Potentially new and re-emerging epidemics.
2.3.3-2: Comprehensive control of Dengue fever under
changing climatic conditions.
2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES.
2.4.1. Cancer. 2.4.1-3: Epidemiology and
aetiology of infection-related cancers.
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN
CITIZENS. 3.3 HEALTH PROMOTION. 3.3-3: Developing
and implementing methods for the transfer of research into
policy in the fields of health promotion and disease
prevention. 3.3-4: A road-map for mental health research in
Europe.
3.4 INTERNATIONAL PUBLIC HEALTH & HEALTH SYSTEMS.
3.4-1: Development and assessment of comprehensive and
integrated interventions and programmes to improve
reproductive health and health equity. 3.4-2: Building
sustainable capacity for research for health and its social
determinants in low and middle income countries. 3.4-3:
Multilateral cooperation between Europe, Africa and Latin
America on public health and health services research.
4. OTHER ACTIONS ACROSS THE HEALTH THEME. 4.1.
COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME.
4.1-1: Networking of major research institutions to
coordinate communication actions aimed at the media and the
general public. 4.1-2: Targeting publication bias. 4.1-3:
Linking EU and Latin American policy making institutions in
the field of health research. 4.1-4: Organisation of
supporting actions and events related to the Presidency of
the European Union.
4.2. RESPONDING TO EU POLICY NEEDS. 4.2-1:
Investigatordriven clinical trials4 on off-patent medicines
for children. 4.2-2: Adverse drug reaction research. 4.2-3:
New methodologies for clinical trials5 in personalised
medicine.
Esquemes de finançament: diferents segons el tema,
consulteu el text complet de la convocatòria.
FP7-HEALTH-2011-two-stage
http://cordis.europa.eu/fp7/dc/index.cfm?fuseaction=UserSite.CooperationDetailsCallPage&call_id=324#infopack
Pressupost indicatiu: 498.000.000 euros
Data límit: 13 de octubre de 2010
Temes convocats:
1.BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES
FOR HUMAN HEALTH. 1.1 HIGH-THROUGHPUT RESEARCH.
1.1-1: SME-targeted research for developing tools and
technologies for high-throughput research. 1.1-2:
Genome-based biomarkers for patient stratification and
pharmacogenomic strategies. 1.4 INNOVATIVE THERAPEUTIC
APPROACHES AND INTERVENTIONS. 1.4-1: Regenerative
medicine clinical trials. 1.4-2: Tools, technologies and
devices for application in regenerative medicine. 1.4-3:
Development and production of new, high-affinity protein
scaffolds for therapeutic use.
2. TRANSLATING RESEARCH FOR HUMAN HEALTH. 2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES:
LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY. 2.1.1
Large-scale data gathering. 2.1.1-2: Proteins and
their interactions in health and disease. 2.1.1-3: Large
scale genomics approaches to identify host determinants of
infectious diseases. 2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN
DEVELOPMENT AND AGEING. 2.2.1. Brain and
brain-related diseases. 2.2.1-1: Investigatordriven
clinical trials4 for childhood-onset neurodegenerative
diseases. 2.2.1-2: Understanding the role of
neuroinflammation in neurodegenerative diseases. 2.2.1-3:
Addictive and/or compulsive behaviour in children and
adolescents: translating pre-clinical results into therapies.
2.2.2. Human development and ageing. 2.2.2-1:
Investigatordriven clinical trials for therapeutic
interventions in elderly populations. 2.2.2-2: Linking human
development and ageing. 2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:
TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH. 2.3.1.
Anti-microbial drug resistance. 2.3.1-1:
Investigatordriven clinical trials6 of off-patent
antibiotics. 2.3.1-4: Development of multi-analyte
diagnostic tests. 2.3.1-5: Development of tools to control
microbial biofilms with relevance to clinical drug
resistance. 2.3.3. Potentially new and re-emerging
epidemics. 2.3.3-1: Identification of factors
promoting the emergence of pathogens with human pandemic
potential from pathogens with a zoonotic background and
related prevention strategies. 2.3.3-3: Development of an
evidence-based behavioural and communication package to
respond to major epidemic outbreaks. 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES.
2.4.1. Cancer. 2.4.1-1: Investigatordriven
treatment trials7 for rare cancers. 2.4.1-2: Translational
research on cancers with poor prognosis. 2.4.2.
Cardiovascular diseases. 2.4.2-1: Investigatordriven
clinical trials8 for the management of cardiovascular
diseases. 2.4.2-2: Evaluation and validation studies of
clinically useful biomarkers in prevention and management of
cardiovascular diseases. 2.4.3. Diabetes and obesity.
2.4.3-1: Investigatordriven clinical trials9 to reduce
diabetes complications. 2.4.3-2: Development of novel
treatment strategies based on knowledge of cellular
dysfunction. 2.4.3-3: Molecular and physiological effects of
lifestyle factors on diabetes/obesity.2.4.3-4: Genetic and
environmental factors in obesity and/or diabetes in specific
populations.
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN
CITIZENS. 3.3 HEALTH PROMOTION. 3.3-1: Developing methodologies
to reduce inequities in the determinants of health. 3.3-2:
Analysis of integrated strategies for sustainable behaviour
change.
Esquemes de finançament: diferents segons el tema,
consulteu el text complet de la convocatòria.
Per a qualsevol consulta, podeu contactar amb Ángeles
Sanchis (ext. 51276,
operuv@uv.es).
Aquest missatge ha estat distribuït a la llista
EUROSALUT
(Oficina Proyectos Europeos UV). Per a subscriure-s’hi,
envieu un missatge a l’adreça
listserv@listserv.uv.es amb el següent text: subscribe EUROSALUT Nom Cognoms. Per a cancel·lar la subscripció,
envieu un missatge a l’adreça
listserv@listserv.uv.es amb el text: signoff EUROSALUT.
